

ACTION REQUEST

Subject: Subcontract Agreement between the University of Michigan and PhasiQ, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the UMOR Conflict of Interest Review Committee. A plan for management of the possible risks associated with the conflict of interest was developed and approved by the Committee and agreed to by the parties involved.

The proposed agreement ("Agreements") falls under the State of Michigan Conflict of Interest Statute because Professor Shuichi Takayama is an employee of the University of Michigan ("University"), and in a leadership role, and is a partial owner of PhasiQ, Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Dr. Takayama, a Professor in the Department of Biomedical Engineering, College of Engineering, is in a leadership role, and is a partial owner of a for-profit company called PhasiQ, Inc. (the "Company"). The Company wishes to fund an NSF (prime) SBIR Phase II project entitled "Crosstalk-Free Multiplexed Immunoassay of Plasma Biomarkers" (ORSP #15-PAF00408) in the Department of Biomedical Engineering under the direction of Dr. Takayama and Dr. Jose Diaz, Research Assistant Professor of Surgery in the Medical School. The purpose of this project is to develop a 9 Plex (protein) cross-reaction-free multiplex vascular injury panel of immunoassays and apply it to analysis of clinical samples from deep vein thrombosis (DVT) patients.

Agreement Terms:

The terms of the Agreement will conform to University policy. The period of performance for the project is approximately twenty-four (24) months. The amount of funding support from Company will not exceed \$190,000. Since research projects are often amended, this agreement includes provisions for changes in time, amount, and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.


### Impact of the Agreement

The Agreement will support an effort by Drs. Takayama and Diaz to use their expertise and University laboratory, as well as other University resources to develop a 9 Plex (protein) cross-reaction-free multiplex vascular injury panel of immunoassays and apply it to analysis of clinical samples from deep vein thrombosis (DVT) patients.

### Recommendation:

This matter has been reviewed and approved by the UMOR Conflict of Interest Review Committee. In light of the disclosure made in this document and our findings that the Agreement was negotiated in conformance with standard University practices. I recommend that the Board of Regents approve of the University's entering into this Agreement with PhasiQ, Inc.

Respectfully submitted,



S. Jack Hu  
Interim Vice President for Research

May 2015